Leonard Post Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Leonard Post sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director directly owned 35,494 shares of the company’s stock, valued at approximately $960,467.64. This represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Stock Up 2.8%

Shares of NASDAQ:QURE opened at $27.57 on Friday. The firm has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The business has a fifty day simple moving average of $22.52 and a 200 day simple moving average of $21.80.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Chardan Capital lifted their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Finally, HC Wainwright lowered their target price on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Hedge Funds Weigh In On uniQure

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc grew its holdings in uniQure by 6.9% in the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in uniQure in the third quarter worth $6,281,000. Farallon Capital Management LLC grew its holdings in uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares during the period. Finally, Boone Capital Management LLC acquired a new stake in uniQure in the third quarter worth $8,599,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.